Share on StockTwits
 

Equities researchers at Piper Jaffray lowered their price objective on shares of Cytokinetics (NASDAQ:CYTK) from $24.00 to $18.00 in a research report issued on Friday, StockRatingsNetwork reports. Piper Jaffray’s price objective would suggest a potential upside of 79.82% from the company’s current price.

Shares of Cytokinetics (NASDAQ:CYTK) traded up 7.75% during mid-day trading on Friday, hitting $10.01. The stock had a trading volume of 1,141,721 shares. Cytokinetics has a 52-week low of $5.76 and a 52-week high of $14.28. The stock has a 50-day moving average of $8. and a 200-day moving average of $7.8. The company’s market cap is $298.7 million.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, February 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.29. The company had revenue of $24.30 million for the quarter, compared to the consensus estimate of $19.14 million. On average, analysts predict that Cytokinetics will post $-1.14 earnings per share for the current fiscal year.

Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.